Bristol-myers Squibb Stock News

Jefferies Managing Director Michael Yee joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

(RTTNews) - Evotec AG (EVTCY.PK), a drug discovery and development company, announced Tuesday that it has expanded its neurodegeneration collaboration with Bristol Myers Squibb (BMY) to include a new targeted protein degradation approach. With the expansion, Evotec receives payments totaling $15 milliobn from Bristol Myers Squibb.

Cell therapy company Century Therapeutics will receive a $100 million up front payment and $50 million in equity investment from Bristol Myers Squibb in a deal announced Monday.

BioAtla (BCAB) has added ~3.1% in the post-market after the company announced a clinical collaboration with Bristol Myers Squibb (BMY) to study its lead candidates BA3011 and BA3021

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical…

Shares of Bristol-Myers Squibb Co (NYSE: BMY) are up more than 3.0% on Monday after the pharmaceutical company said it will repurchase $5.0 billion worth of its stock in Q1. CEO says business developm

Sellers continue to push their advantage making it necessary to play defense to win. Here are three top stock trades for the new week.

Jim Lebenthal, Cerity Partners chief equity strategist, and Joe Terranova, Virtus Investment Partners senior managing partner, join the 'Halftime Report' to discuss the biotech and health-care sectors

Ahead of its presentation at the Annual J.P. Morgan Healthcare Conference today, Bristol Myers Squibb (BMY) announced an accelerated share repurchase agreement for the first quarter of…

Dr. Giovanni Caforio, Bristol Myers Squibb CEO, joins the 'Halftime Report' to discuss his company's collaboration with Century Therapeutics.

Century Therapeutics Inc (NASDAQ: IPSC ) and Bristol Myers Squibb Co (NYSE: BMY ) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could … Full story available on Benzinga.com

Bristol Myers Squibb Co (NYSE: BMY) kicked off the Big Pharma presentations at the J.P. Morgan healthcare conference.

Century Therapeutics (IPSC) soars 13.5% premarket after announcing research collaboration and license agreement with and Bristol Myers Squibb (BMY) to develop and commercialize up to

Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced a $5 billion buyback and issued FY22 financial guidance. Bristol-Myers said it plans to execute the accelera